Risk of adverse events with fibrates

Alawi A Alsheikh-Ali; Jeffrey T Kuvin; Richard H Karas

doi:10.1016/j.amjcard.2004.06.033

Risk of adverse events with fibrates

Am J Cardiol. 2004 Oct 1;94(7):935-8. doi: 10.1016/j.amjcard.2004.06.033.

Authors

Alawi A Alsheikh-Ali¹, Jeffrey T Kuvin, Richard H Karas

Affiliation

¹ Molecular Cardiology Research Institute, Department of Medicine, Division of Cardiology, Tufts-New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts 02111, USA.

PMID: 15464682
DOI: 10.1016/j.amjcard.2004.06.033

Abstract

An increased risk for adverse events was observed with gemfibrozil relative to fenofibrate, predominantly driven by an increased rate of rhabdomyolysis. This difference was especially noticeable in patients taking the combination of gemfibrozil and a statin, particularly cerivastatin.

Publication types

Comparative Study

MeSH terms

Aged
Chemical and Drug Induced Liver Injury
Female
Fenofibrate / adverse effects*
Gemfibrozil / adverse effects
Humans
Hyperlipidemias / drug therapy
Hypolipidemic Agents / adverse effects*
Liver Diseases / epidemiology
Male
Middle Aged
Rhabdomyolysis / chemically induced*
Rhabdomyolysis / epidemiology*
Risk Factors
Treatment Failure
United States / epidemiology

Substances

Hypolipidemic Agents
Gemfibrozil
Fenofibrate